Disease Models & Mechanisms (Feb 2025)
Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibition
- Stephanie Ling,
- Alex Dexter,
- Alan M. Race,
- Shreya Sharma,
- Gregory Hamm,
- Urszula M. Polanska,
- Rosetta Consortium Cancer Research UK,
- John F. Marshall,
- Zoltan Takats,
- Kevin Brindle,
- Mariia O. Yuneva,
- George Poulogiannis,
- Andrew D. Campbell,
- Owen J. Sansom,
- Richard J. A. Goodwin,
- Josephine Bunch,
- Simon T. Barry
Affiliations
- Stephanie Ling
- Imaging and Data Analytics, AstraZeneca, Cambridge CB2 0AA, UK
- Alex Dexter
- National Physical Laboratory, Teddington TW11 0LA, UK
- Alan M. Race
- National Physical Laboratory, Teddington TW11 0LA, UK
- Shreya Sharma
- National Physical Laboratory, Teddington TW11 0LA, UK
- Gregory Hamm
- Imaging and Data Analytics, AstraZeneca, Cambridge CB2 0AA, UK
- Urszula M. Polanska
- Early Oncology, AstraZeneca, Cambridge CB2 0AA, UK
- Rosetta Consortium Cancer Research UK
- https://www.cancergrandchallenges.org/rosetta
- John F. Marshall
- Barts Cancer Institute, London EC1M 6AU, UK
- Zoltan Takats
- Imperial College London, London SW7 2AZ, UK
- Kevin Brindle
- The Rosalind Franklin Institute, Harwell Campus, Didcot OX11 0QS, UK
- Mariia O. Yuneva
- Francis Crick Institute, London NW1 1AT, UK
- George Poulogiannis
- Institute of Cancer Research, London SW3 6JB, UK
- Andrew D. Campbell
- CRUK Scotland Institute, Glasgow G61 1BD, UK
- Owen J. Sansom
- CRUK Scotland Institute, Glasgow G61 1BD, UK
- Richard J. A. Goodwin
- Imaging and Data Analytics, AstraZeneca, Cambridge CB2 0AA, UK
- Josephine Bunch
- National Physical Laboratory, Teddington TW11 0LA, UK
- Simon T. Barry
- Early Oncology, AstraZeneca, Cambridge CB2 0AA, UK
- DOI
- https://doi.org/10.1242/dmm.050804
- Journal volume & issue
-
Vol. 18,
no. 2
Abstract
No abstracts available.Keywords